|

Xaluritamig Clinical Trials

5 actively recruiting trials across 5 locations

Also known as: AMG 509

Pipeline

Phase 1: 3Phase 3: 2

Top Sponsors

  • Amgen5

Indications

  • Cancer5
  • Metastatic Castration-resistant Prostate Cancer2
  • Metastatic Hormone-sensitive Prostate Cancer (mHSPC)1
  • Ewing Sarcoma1
  • Prostate Cancer1

Birmingham, Alabama1 trial

Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)

University of Alabama at Birmingham

Phase 3

Duarte, California1 trial

A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer

City of Hope National Medical Center

Phase 3

Los Angeles, California1 trial

Evaluation of Xaluritamig in Adults, Adolescents and Children With Relapsed or Refractory Ewing Sarcoma (EWS)

University of California Los Angeles

Phase 1

San Francisco, California1 trial

Evaluation of Neoadjuvant Xaluritamig in Localized Prostate Cancer

University of California San Francisco

Phase 1

Boston, Massachusetts1 trial

Study Evaluating the Safety, Tolerability, and Efficacy of Xaluritamig in Combination With Androgen Receptor Pathway Inhibitors in Participants With Metastatic Hormone-sensitive Prostate Cancer

Dana Farber Cancer Institute

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.